Fixed-Dose Combination of Cefepime Plus Amikacin (Potentox) Inhibits Pneumonia Infection

Abstract

Pneumonia is a severe infection that causes high morbidity and mortality rate worldwide. It is caused by Klebsiella pneumoniae, which generally causes upper respiratory tract infection. In case of such type of infection, levels of oxidant and antioxidant become imbalanced, which may contribute to lung injury. The present study was planned to evaluate the status of oxidant and antioxidant enzyme activities in plasma and lung tissue of pneumonia-infected rats model. Animals were randomly distributed into 3 groups of 8 rats each: groups I (control, normal saline treated), II (infected group), and III (infected + treated group). The findings showed that there was significant increase (P < .001) in body temperature along with decreased body weight in the infected group as compared to the control group. Similarly, all the activities of antioxidant enzymes (superoxide dismutase [SOD], catalase) were significantly decreased along with increased malonaldialdehyde (MDA) levels in plasma and lung tissue of the infected group as compared to the control group. These enzyme activities along with MDA levels were improved and came back near to normal level after administration of cefepime plus amikacin (potentox) for 7 days in group III. These studies concluded that fixed-dose combination of potentox improved oxidant and antioxidant levels in pneumonia infection.

Comparative Study of CSE 1034 and Ceftriaxone in Pneumonia Induced Rat

“…The results also indicated that CSE1034 showed free radical scavenger property than ceftriaxone alone which reduced free radical mediated tissue injury. Various studies have reported that cephalosporin and sulbactam antibiotics showed free radical scavenger property and their effect on inhibition of neutrophil function [25]. The conclusion of this study revealed that a novel CSE1034 showed better antimicrobial effect and free radical scavenger property which inhibits the free radical tissue injury and inflammatory response in the lung during pneumonia infection and is a safer and more effective drug.…”

Cefepime: A Review of Its Use in the Treatment of Serious Bacterial Infections

“…87 Combination therapy vs. monotherapy Combination of cefepime with an aminoglycoside or fluoroquinolone is useful and safe empiric treatment for serious infections. 88,89 It is supposed to be synergistic; though this synergy is poorly supported. Damas P et al studied cefepime combination therapy vs. monotherapy in ventilator-associated pneumonia and found that addition of an aminoglycoside or fluoroquinolone gave no clinical or bacteriologic benefit.…”

Advancing in the Direction of Right Solutions: Treating Multidrug-Resistant Pneumonia

“…Many studies have highlighted that adjuvants co-administered with antibiotics reduce the oxidative stress, which in turn reduce inlammation [76,77]. Dwivedi et al [78] reported that AAE used for 21 days, the levels of antioxidant enzymes (superoxidase dismutase, catalase, glutathione reductase, glutathione peroxidase), along with xanthine oxidase, lipid peroxidation, myeloperoxidase (MPO) levels, hepatic, and renal parameters were signiicantly improved in plasma and tissues of the AAEtreated group indicating antioxidant or free radical scavenging properties [50].…”

“…Amikacin is one of the most commonly used aminoglycosides and it has the highest recommendation from IDSA 2016 for usage in nosocomial pneumonia cases as an empirical antibiotic in the combination protocol against nosocomial pneumonia. Potentox (cefepime + amikacin) is not just the most active combination in vitro [23,49] but also has demonstrated eicacy in vivo as the most active combination [50,51].…”